Crossmark

SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH)

Crossref DOI link: https://doi.org/10.1038/s41598-024-67843-8

Published Online: 2024-07-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sivakumar, Pitchumani

Saul, Michelle

Robinson, Douglas

King, Lindsay E.

Amin, Neeta B.
License Information

Text and Data Mining valid from 2024-07-24

Version of Record valid from 2024-07-24
More Information

Article History

Received: 25 April 2024

Accepted: 16 July 2024

First Online: 24 July 2024

Competing interests

: All authors were Pfizer employees at the time of the work and shareholders of Pfizer Inc.

Document is current

Any future updates will be listed below